Securian Asset Management Inc. Sells 406 Shares of Hologic, Inc. (NASDAQ:HOLX)

Securian Asset Management Inc. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the 2nd quarter, Holdings Channel reports. The firm owned 13,419 shares of the medical equipment provider’s stock after selling 406 shares during the quarter. Securian Asset Management Inc.’s holdings in Hologic were worth $996,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Czech National Bank raised its position in shares of Hologic by 7.7% in the 2nd quarter. Czech National Bank now owns 44,473 shares of the medical equipment provider’s stock worth $3,302,000 after acquiring an additional 3,172 shares in the last quarter. SG Americas Securities LLC boosted its stake in Hologic by 583.1% during the 2nd quarter. SG Americas Securities LLC now owns 229,171 shares of the medical equipment provider’s stock valued at $17,016,000 after purchasing an additional 195,623 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Hologic by 16.8% during the 2nd quarter. QRG Capital Management Inc. now owns 89,162 shares of the medical equipment provider’s stock valued at $6,620,000 after purchasing an additional 12,845 shares during the last quarter. BDF Gestion acquired a new position in Hologic during the 2nd quarter valued at about $1,872,000. Finally, Atwood & Palmer Inc. boosted its stake in Hologic by 1.4% during the 2nd quarter. Atwood & Palmer Inc. now owns 354,335 shares of the medical equipment provider’s stock valued at $26,309,000 after purchasing an additional 5,008 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Evercore ISI lifted their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Royal Bank of Canada lifted their price target on Hologic from $81.00 to $82.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Finally, Argus boosted their target price on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $87.60.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock valued at $1,469,973 over the last three months. Corporate insiders own 1.75% of the company’s stock.

Hologic Trading Down 2.0 %

HOLX stock traded down $1.69 during trading on Monday, reaching $81.95. The company had a trading volume of 1,033,385 shares, compared to its average volume of 1,645,164. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The company has a market cap of $19.13 billion, a P/E ratio of 41.82, a PEG ratio of 2.64 and a beta of 0.99. The business has a 50 day moving average of $76.29 and a 200 day moving average of $75.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $0.93 earnings per share. Hologic’s revenue was up 2.7% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.